Hemochromatosis secondary prevention

Revision as of 18:39, 1 January 2019 by Shyam Patel (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Hemochromatosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hemochromatosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hemochromatosis secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hemochromatosis secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hemochromatosis secondary prevention

CDC on Hemochromatosis secondary prevention

Hemochromatosis secondary prevention in the news

Blogs on Hemochromatosis secondary prevention

Directions to Hospitals Treating Hemochromatosis

Risk calculators and risk factors for Hemochromatosis secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Shyam Patel [2]; Associate Editor(s)-in-Chief: Sunny Kumar MD [3]

Overview

We can treat hemochromatosis with many options depending on level and cause of increased iron load in body.

Secondary Prevention

Hemochromatosis can be prevented secondarily by:[1][2]

  • Dietary modifications: This includes avoidance of excess vitamin C, red meat, iron supplements, and alcohol.
  • Phlebotomy: This can be done routinely, typically once every few weeks or months, to prevent iron accumulation.
  • Iron chelation therapy: The use of iron chelators is not common for hemochromatosis, but the chelators can be used for secondary iron overload conditions.
  • Genetic testing: Mutational analysis of the HFE gene mutations, including C282Y and H63D, is particularly useful in patients with a family history (or suspected family history) of hemochromatosis.

References

  1. de Souza AF, Carvalho-Filho RJ, Chebli JF (2001). "[Hereditary hemochromatosis. Case report and review of the literature]". Arq Gastroenterol. 38 (3): 194–202. PMID 11917720.
  2. Kew MC (2005). "Prevention of hepatocellular carcinoma". HPB (Oxford). 7 (1): 16–25. doi:10.1080/13651820410024030. PMC 2023918. PMID 18333157.

Template:WS Template:WH